Poly Medicure Limited share price

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dial…Read more

Website NSE हिंदी में BSE

HealthcareMedical Instruments & SuppliesNifty 500 Nifty Smallcap 250NSE: POLYMEDISIN INE205C01021

16 Oct 2026, 3:29 PM IST₹1,593.80▲ 10.00 (0.63%)

Market Cap₹ 16,155 Cr.
Current Price₹ 1,593.80
High / Low₹ 2,094 / 1,182
Stock P/E51.3
Book Value₹ 306
Dividend Yield0.22 %
ROCE13.3 %
ROE11.30 %
Face Value₹ 5.0

More figures (10)

EPS (TTM)₹ 31.06
Price / Book5.20
OPM17.4 %
Debt / Equity0.11
Sales growth (5Y)19.0 %
Profit growth (5Y)18.7 %
Promoter holding63.6 %
EV / EBITDA34.4
Beta0.00
All-time high₹ 3,358

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
POLYMED	-6.50%	-7.48%	+6.47%	-10.14%	-17.01%	+5.17%	+10.69%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Poly Medicure Limited is in the Medical Instruments & Supplies industry (Healthcare), with a market value of ₹16,155 crore.
It trades at 51.3 times its last 12 months' earnings and 5.2 times book value.
Revenue grew 19.0% a year over the last 5 years, profit 18.7% a year.
Return on equity was 11.3% and return on capital employed 13.3% in the latest year.
Debt was 0.11 times shareholders' equity.
The share price is 23.9% below its 52-week high and down 17.0% over one year.
Promoters and insiders hold about 63.6%; institutions about 18.1%.

Pros

Sales have grown 19.0% a year over the last 5 years.
Profit has grown 18.7% a year over the last 5 years.
Healthy return on equity of 15.4% on average over the last 3 years.
Trades at 51.3 times earnings, below its 3-year median of 67.7.
Promoters have raised their holding by 9.26 points over 3 years, to 62.42%.

Cons

No standout weaknesses in the reported figures.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Poly Medicure Limited

Employees: 2,614
Head office: New Delhi
NSE industry: Healthcare

HealthcareHealthcareMedical Instruments & Supplies

Part ofNifty 500 Nifty Smallcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Poly Medicure	1,593.80	51.3	16,155	0.22	85	-8.39	525	30.30	13.3	11.3	5.20	17.4	0.11	63.58	1,875	19.0
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Apollo Hospitals Enterprise	7,890.00	54.3	1,13,446	0.25	581	49.05	7,044	25.95	19.2	21.9	11.97	11.7	0.90	28.39	24,911	14.8
6.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
7.	Lenskart Solutions	646.50	174.7	1,11,938	0.00	222	1.35	2,714	57.11	7.2	6.7	12.85	8.8	0.35	38.60	8,790	35.4
8.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
9.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
10.	Max Healthcare Institute	846.00	56.7	82,342	0.23	323	4.87	2,366	16.70	12.6	14.3	7.66	22.8	0.32	28.20	8,225	22.4
	Median: 10 Co.	1,459.45	52.8	1,11,979	0.29	573	2.32	5,982	21.59	14.6	14.5	6.43	19.6	0.27	45.30	19,445	14.1

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	321	337	340	378	385	420	424	441	403	444	494	535	525
YOY Sales Growth %		22.79%	19.23%	23.21%	19.93%	24.52%	24.92%	16.60%	4.79%	5.68%	16.37%	21.25%	30.30%
	234	253	249	281	281	305	310	321	297	329	382	424	400
Material Cost %	35%	36%	35%	35%	33%	32%	35%	33%	32%	31%	32%	33%	27%
Employee Cost %	18%	17%	18%	18%	18%	19%	18%	18%	19%	20%	23%	24%	24%
Other Expenses %	20%	22%	21%	21%	21%	22%	20%	22%	23%	24%	23%	22%	25%
Operating Profit	87	84	90	97	104	115	115	119	106	115	111	110	125
OPM %	27%	25%	27%	26%	27%	27%	27%	27%	26%	26%	23%	21%	24%
	13	14	17	15	17	26	22	24	42	34	26	18	33
Exceptional items	1										-7
Interest	2	2	3	3	3	3	3	2	3	3	6	6	7
Depreciation	16	16	16	16	20	21	22	21	23	25	29	38	36
Profit before tax	83	80	87	92	98	117	112	121	122	121	96	84	116
	25%	23%	26%	26%	25%	26%	25%	26%	25%	25%	28%	24%	28%
Current tax	20	17	20	20	23	25	24	24	22	27	26	25	28
Deferred tax	1	2	3	4	2	5	4	7	8	2	0	-5	4
	63	62	65	68	74	87	85	92	93	92	71	65	85
Profit from associates		1	1	0	0	1	2	2	1	1	2	2	2
Minority share										-0	-0	-1	-1
Profit to shareholders	63	62	65	68	74	87	85	92	93	92	71	66	86
YOY Profit Growth %		42.97%	30.01%	16.23%	18.09%	40.63%	31.09%	34.34%	25.72%	4.97%	-16.92%	-29.18%	-8.39%
EPS in Rs	6.54	6.48	6.78	7.12	7.71	9.01	8.48	8.92	9.19	9.06	7.00	6.54	8.49
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	306	320	321	361	367	402	411	421	384	417	419	443	431
YOY Sales Growth %	27.85%	21.18%	18.08%	23.05%	20.25%	25.81%	28.07%	16.64%	4.52%	3.50%	1.93%	5.24%	12.25%
	220	237	236	264	266	290	295	305	282	305	307	322	310
Material Cost %	34%	35%	35%	34%	33%	31%	34%	34%	32%	30%	32%	33%	28%
Employee Cost %	18%	17%	18%	17%	18%	18%	18%	17%	18%	20%	20%	18%	21%
Other Expenses %	20%	22%	21%	21%	21%	22%	20%	21%	24%	23%	21%	22%	23%
Operating Profit	85	83	84	97	101	113	116	116	102	111	112	121	121
OPM %	28%	26%	26%	27%	28%	28%	28%	28%	26%	27%	27%	27%	28%
	13	13	17	16	17	27	22	24	41	34	30	15	29
Exceptional items											-7
Interest	2	2	3	3	3	3	3	2	3	3	4	4	4
Depreciation	15	15	16	16	19	20	21	21	23	24	25	26	26
Profit before tax	81	78	82	94	96	117	113	116	117	118	106	107	119
	25%	24%	25%	25%	25%	25%	25%	26%	25%	25%	26%	25%	26%
Current tax	20	17	18	20	22	24	24	22	21	27	26	23	25
Deferred tax	1	2	3	4	2	5	4	8	8	2	2	3	5
	61	59	61	71	72	87	85	87	88	89	78	81	88
YOY Profit Growth %	110.15%	30.93%	29.28%	22.70%	19.46%	47.32%	38.55%	22.87%	21.61%	2.10%	-7.95%	-6.97%	0.22%
EPS in Rs	6.31	6.17	6.41	7.35	7.53	8.99	8.48	8.40	8.68	8.79	7.73	7.95	8.69
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
		611	687	786	923	1,115	1,376	1,670	1,875	1,997
YOY Sales Growth %			12.51%	14.44%	17.37%	20.82%	23.36%	21.37%	12.30%
		481	523	572	710	850	1,018	1,217	1,433	1,536
Material Cost %		34%	32%	33%	38%	36%	35%	33%	32%	31%
Employee Cost %		19%	20%	18%	18%	18%	18%	18%	21%	23%
Other Expenses %		26%	24%	21%	21%	22%	21%	22%	23%	24%
Operating Profit		129	164	214	213	265	358	453	442	461
OPM %		21%	24%	27%	23%	24%	26%	27%	24%	23%
		18	18	18	38	36	59	89	120	111
Exceptional items		1							-7	-7
Interest		12	18	9	4	9	11	12	18	22
Depreciation		37	41	48	54	57	64	83	116	128
Profit before tax		100	124	177	193	236	342	447	422	416
		35%	24%	25%	25%	25%	25%	25%	25%	26%
Current tax		32	34	44	46	59	77	96	101
Deferred tax		3	-4	-0	3	-1	9	18	5
		65	96	136	147	179	258	339	321	313
Profit from associates			2	3	2	2	3	5	6	6
Minority share									-1	-2
Profit to shareholders						179	258	339	322	315
YOY Profit Growth %			46.60%	41.72%	7.82%	22.37%	44.05%	31.09%	-5.27%
EPS in Rs	1.83	7.41	10.86	15.25	15.28	18.69	26.92	34.13	31.79	31.09
Dividend Payout %						13%	11%	9%	11%

Compounded Sales Growth

5 Years:: 19%
3 Years:: 19%
TTM:: 18%

Compounded Profit Growth

5 Years:: 19%
3 Years:: 21%
TTM:: -12%

Stock Price CAGR

5 Years:: 11%
3 Years:: 5%
1 Year:: -17%

Return on Equity

4 Years:: 15%
Last Year:: 11%

₹ Cr	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	120	646	747	879	1,068	1,307	1,602	1,662	1,710
YOY Sales Growth %		436.93%	15.66%	17.66%	21.46%	22.40%	22.53%	3.79%
	100	486	539	667	804	958	1,156	1,216	1,244
Material Cost %	36%	31%	33%	37%	36%	35%	33%	32%	31%
Employee Cost %	17%	20%	17%	17%	18%	18%	17%	19%	20%
Other Expenses %	31%	25%	22%	22%	22%	21%	22%	22%	22%
Operating Profit	20	160	208	212	264	350	445	446	465
OPM %	17%	25%	28%	24%	25%	27%	28%	27%	27%
	6	19	19	39	36	58	90	120	107
Exceptional items								-7	-7
Interest	1	18	8	4	8	11	11	13	15
Depreciation	6	39	46	53	56	62	81	98	101
Profit before tax	19	122	173	195	237	335	443	448	449
	17%	24%	25%	25%	24%	25%	25%	25%	25%
Current tax	2	33	44	46	59	74	93	97
Deferred tax	2	-4	-0	3	-1	9	19	15
	16	92	130	146	179	252	331	336	336
YOY Profit Growth %		471.31%	40.19%	12.74%	22.62%	40.59%	31.63%	1.40%
EPS in Rs	1.83	10.47	14.54	15.23	18.67	26.24	33.40	33.15	33.16
Dividend Payout %					13%	11%	9%	11%

Compounded Sales Growth

5 Years:: 17%
3 Years:: 16%
TTM:: 6%

Compounded Profit Growth

5 Years:: 21%
3 Years:: 23%
TTM:: -3%

Stock Price CAGR

5 Years:: 11%
3 Years:: 5%
1 Year:: -17%

Return on Equity

4 Years:: 15%
Last Year:: 11%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	48	48	51	51
Reserves	1,194	1,422	2,715	3,055
	149	174	180	354
Long term borrowings	18	1		52
Short term borrowings	129	169	178	290
	187	215	247	459
Trade payables	92	96	86	123
Minority interest				43
Current liabilities	293	351	370	576
Total Liabilities	1,577	1,859	3,192	3,919
	699	921	1,178	1,354
Gross block	1,066	1,342	1,664	1,354
Accumulated depreciation	366	421	486
Goodwill & intangibles	50	54	55	439
CWIP	110	99	138	91
	768	839	1,876	2,474
Inventories	209	221	286	434
Trade receivables	235	270	350	531
Cash & equivalents	7	12	9	51
Current assets	807	842	1,917	1,942
Total Assets	1,577	1,859	3,192	3,919

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	191	266	233	246
Profit for the year	179	258	339	331
Working capital changes	-49	-41	-155	-149
Direct taxes paid	-58	-74	-92	-102
	-179	-241	-1,187	-225
Fixed assets purchased	-239	-277	-331	-308
Fixed assets sold	0	2	1	3
	-13	-20	951	20
Interest paid	-8	-11	-11	-16
Dividends paid	-24	-29	-30	-35
Net Cash Flow	-1	5	-4	41
Free Cash Flow	-48	-11	-98	-62

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	14.4%	19.0%	16.0%	11.3%
ROCE	—	19.2%	23.5%	16.5%	13.3%
Operating margin	—	19.6%	22.2%	22.2%	17.4%
Net margin	—	16.2%	18.9%	20.3%	17.7%
Debt / equity	—	0.12	0.12	0.07	0.11
Current ratio	—	2.75	2.40	5.18	3.37
Debtor days	—	78	72	76	103
Inventory days	—	150	133	188	265
Days payable	—	66	58	57	75
Cash conversion cycle	—	162	147	207	293
Working capital days	—	169	131	338	266

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 62.42%
FIIs 5.57%
DIIs 16.08%
Public 15.94%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	53.16%	53.16%	53.15%	66.03%	62.56%	62.44%	62.44%	62.44%	62.42%	62.42%	62.42%	62.42%
	14.49%	14.10%	12.38%	9.91%	11.87%	12.33%	11.46%	11.41%	9.77%	9.40%	5.91%	5.57%
Foreign portfolio investors (Cat. I)	14.25%	13.89%	12.26%	9.75%	11.31%	11.66%	10.36%	10.34%	9.08%	8.84%	5.68%	5.40%
Foreign portfolio investors (Cat. II)	0.24%	0.21%	0.11%	0.16%	0.55%	0.65%	1.08%	1.07%	0.69%	0.57%	0.24%	0.16%
	5.15%	5.45%	7.22%	9.35%	12.33%	11.66%	11.96%	11.72%	13.54%	13.84%	15.59%	16.08%
Mutual funds	3.95%	4.18%	4.99%	6.29%	7.35%	7.17%	7.16%	7.34%	8.04%	8.14%	8.84%	9.61%
Insurance companies	0.99%	1.11%	2.01%	2.31%	3.06%	2.44%	2.77%	2.70%	2.83%	3.09%	3.34%	2.99%
Alternative investment funds	0.21%	0.17%	0.21%	0.74%	1.92%	2.05%	2.03%	1.68%	2.66%	2.61%	3.42%	3.48%
	27.20%	27.29%	27.26%	14.72%	13.24%	13.57%	14.15%	14.44%	14.27%	14.34%	16.08%	15.94%
Retail (up to ₹2 lakh)	4.72%	4.79%	4.79%	4.88%	4.16%	4.64%	5.17%	5.48%	5.46%	5.81%	6.93%	7.34%
HNIs (above ₹2 lakh)	6.63%	6.59%	6.55%	6.49%	5.97%	5.91%	5.90%	5.89%	5.80%	5.49%	5.67%	4.84%
NRIs	0.76%	0.74%	0.75%	0.77%	0.69%	0.72%	0.77%	0.78%	0.76%	0.77%	0.65%	0.87%
Bodies corporate	15.06%	15.14%	15.15%	2.57%	2.37%	2.25%	2.24%	2.24%	2.22%	2.23%	2.51%	2.73%
No. of Shareholders	34,649	36,053	36,712	36,852	38,352	60,686	65,583	71,142	64,400	67,750	73,414	73,643

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Poly Medicure

Holder (above 1%)	Stake
Quant Mutual Fund - Qsif Hybrid Long-Short FundMutual fund	4.61%
Lighthouse India Fund Iv AifAIF	2.33%
Axis Max Life Insurance Limited A/C Uegfh - High Growth Fund IiInsurance	2.14%
Uti-Unit Linked Insurance PlanMutual fund	1.52%
SBI NIFTY SMALLCAP 250 ETFMutual fund · see the fund house	1.22%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 9.61% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 28 Aug 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

Poly Medicure (POLYMED.NS) Eases 1.27% to ₹1,584.8 as ₹1,505 Support Comes Into Focus - ATR Trailing Stophttps://www.siam.in/ · 9 Oct 2026

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Poly Medicure Limited

What is the share price of Poly Medicure Limited today?

Poly Medicure Limited (POLYMED) last traded at ₹1,593.80 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Poly Medicure Limited?

About ₹16,155 crore at the latest price.

What is the P/E ratio of Poly Medicure Limited?

About 51.3 times its earnings over the last 12 months.

Is Poly Medicure Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Poly Medicure Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Poly Medicure Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Poly Medicure Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Poly Medicure

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Poly Medicure Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next